TEAR HERE



ATTENTION PHARMACISTS: Detach "Patient Information" from package insert and dispense with product.


Flomax® (tamsulosin hydrochloride) Capsules, 0.4 mg

Prescribing Information

DESCRIPTION

in hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate Tamsulosin hydrochloride is (-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride. Tamsulosin hydrochloride is a white crystalline powder that melts with decomposition at approximately 230°C. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether.

The empirical formula of tamsulosin hydrochloride is C20H28N2O5S • HCI. The molecular veight of tamsulosin hydrochloride is 444.98. Its struct



Each FLOMAX capsule for oral administration contains tamsulosin hydrochloride 0.4 mg. Each FLOMAX capsule for oral administration contains tamsulosin hydrochloride 0.4 mg, and the following inactive ingredients: methacrylic acid copolymer, microcrystalline cellu-lose, triacetin, polysorbate 80, sodium lauryl sulfate, calcium stearate, talc, FD&C blue No. 2, titanium dioxide, ferric oxide, gelatin, and trace amounts of shellac, industrial methylatec spirit 74 OP, *n*-butyl alcohol, isopropyl alcohol, propylene glycol, dimethylpolysiloxane, and black iron oxide E172.

CLINICAL PHARMACOLOGY The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and ophamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha1 adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adreno-ceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH.

Tamsulosin, an alpha₁ adrenoceptor blocking agent, exhibits selectivity for alpha₁ receptors in the human prostate. At least three discrete alpha₁-adrenoceptor subtypes have been identified: alpha_{1A}, alpha_{1B} and alpha_{1D}; their distribution differs between human organs and tissue. Approximately 70% of the alpha₁-receptors in human prostate are of the alpha_{1A} subtype.

Flomax[®] (tamsulosin hydrochloride) capsules are not intended for use as an antihypertensive drug.

Pharmacokinetics The pharmacokinetics of tamsulosin hydrochloride have been evaluated in adult healthy vol-unteers and patients with BPH after single and/or multiple administration with doses rang-


Absorption

Absorption of tamsulosin hydrochloride from FLOMAX capsules 0.4 mg is essentially com-plete (>90%) following oral administration under fasting conditions. Tamsulosin hydrochlo-ride exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-a-day dosing.

Effect of Food

Effect of Food The time to maximum concentration (T_{max}) is reached by four to five hours under fasting conditions and by six to seven hours when FLOMAX capsules are administered with food. Taking FLOMAX capsules under fasted conditions results in a 30% increase in bioavailabil (AUC) and 40% to 70% increase in peak concentrations (C_{max}) compared to fed conditio (Figure 1).

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose nistration of FLOMAX capsules 0.4 mg Under Fasted and Fed Conditions Admi (n=8)



The effects of food on the pharmacokinetics of tamsulosin hydrochloride are consistent regardless of whether a Flomax® (tamsulosin hydrochloride) capsule is taken with a light breakfast or a high-fat breakfast (Table 1).

Mean (± S.D.) Pharmacokinetic Parameters Following FLOMAX capsules 0.4 mg Once Daily or 0.8 mg Once Daily with a Light Breakfast, High-Fat Breakfast or Fasted Table 1

kinetic 0.4 mg QD to healthy 0.8 mg QD to healthy volunt s: n=22 Parameter (age range 55-75 years) volunteers; n=23 (age range 18-32 years) High-Fat Light Fasted Light Fasted Breakfast Breakfast Breakfast
 Dreakfast

 12.3 ± 6.7
 13.5 ± 7.6
 13.3 ± 13.3

 29.8 ± 10.3
 29.1 ± 11.0
 41.6 ± 15.6

 2.7 ± 0.7
 2.5 ± 0.8
 3.6 ± 1.1

 7.0
 6.6
 5.0
 Cmin (ng/mL) Cmax (ng/mL) Cmax/Cmin Ratio Tmax (hours) T1/2 (hours) 3.8 ± 2.5 17.1 ± 17.1 5.3 ± 2.2 4.04.0 ± 2.0 10.1 ± 4.8 3.1 ± 1.0

AUCτ (ng•hr/ 151 ± 81.5 440 ± 195 199 ± 94.1 449 ± 217

meentration 449 ± 449 \pm 449 \pm

ed half-life

AUC τ = Area under the tamsulosin hydrochloride plasma time curve over the dosing interval

Boehringer Boehringer Ingelheim

Distribution The mean steady-state apparent volume of distribution of tamsulosin hydrochloride after intravenous administration to ten healthy male adults was 16L, which is suggestive of distrib-ution into extracellular fluids in the body. Additionally, whole body autoradiographic studies in mice and rats and tissue distribution in rats and dogs indicate that tamsulosin hydrochlo indice is whele distributed to most tissues including kidney, prostate, liver, gall bladder, heart, aorta, and brown fat, and minimally distributed to the brain, spinal cord, and testes.

Tamsulosin hydrochloride is extensively bound to human plasma proteins (94% to 99%), primarily alpha-1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL). The results of two-way *in vitro* studies indicate that the binding of tamsulosin hydrochloride to human plasma proteins is not affected by amitriptyline, diclofenac, glyburide, simvastatin plus simvastatin-hydroxy acid metabolite, warfarin, dicate the substantiation of the subst opranolol, trichlormethiazide, or chlormadinone. Likewise, tamsulosin diazepam, p hydrochloride had no effect on the extent of binding of these drugs.

Metabolism There is no enantiomeric bioconversion from tamsulosin hydrochloride [R(-) isomer] to the S(+) isomer in humans. Tamsulosin hydrochloride is extensively metabolized by cytochrome P4S0 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been estab-lished. Additionally, the cytochrome P4S0 enzymes that primarily catalyze the Phase I metabolism of tamsulosin hydrochloride have not been conclusively identified. Therefore, possible interactions with other cytochrome P4S0 metabolized compounds cannot be dis-cerned with current information. The metabolites of tamsulosin hydrochloride undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Incubations with human liver microsomes showed no evidence of clinically significant meta Incubations with numan liver microsomes showed no evidence of clinically significant n bolic interactions between tamsulosin hydrochloride and amitriptyline, albuterol (beta a nist), glyburide (glibenclamide) and finasteride (Salpha-reductase inhibitor for treatmer BPH). However, results of the *in vitro* testing of the tamsulosin hydrochloride interaction with diclofenac and warfarin were equivocal. orol (beta ag

Excretion

Metabolism

ation of the radiolabeled dose of tamsulosin hydrochloride to four healthy vol-On admini unteers, 97% of the administered radioactivity was recovered, with urine (76%) representing the primary route of excretion compared to feces (21%) over 168 hours

Following intravenous or oral administration of an immediate-release formulation, the elimi Following intravenous of oral administration of an immediate-release formulation, the elimi-nation half-life of tamsulosin hydrochloride in plasma range from five to seven hours. Because of absorption rate-controlled pharmacokinetics with Flomax® (tamsulosin hydrochloride) capsules, the apparent half-life of tamsulosin hydrochloride is approximately 9 to 13 hours in healthy volunteers and 14 to 15 hours in the target population.

Tamsulosin hydrochloride undergoes restrictive clearance in humans, with a relatively low

systemic clearance (2.88 L/h). Special Populations

Special Populations Geriatrics (Age) Cross-study comparison of FLOMAX capsules overall exposure (AUC) and half-life indicate that the pharmacokinetic disposition of tamsulosin hydrochloride may be slightly prolonged in geriatric males compared to young, healthy male volunteers. Intrinsic clearance is inde-pendent of tamsulosin hydrochloride binding to AAG, but diminishes with age, resulting in a 40% overall higher exposure (AUC) in subjects of age 55 to 75 years compared to subjects of age 20 to 32 years. age 20 to 32 years.

Renal Dysfunction

The pha macokinetics of tamsulosin hydrochloride have been compared in 6 subjects with The pharmacokinetics of tamsulosin hydrochloride have been compared in 6 subjects with mild - moderate (30sCL_{cr} < 70 mL/min/1.73m²) or moderate-severe (10 sCL_{cr} < 30 mL/min/1.73m²) nampairment and 6 normal subjects (CL_{cr} < 90 mL/min/1.73m²). While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride, as well as the intrinsic clearance, remained relatively constant. Therefore, patients with renal impairment do not require an adjustment in Flomax[®] (tamsulosin hydrochloride) capsules dosing. However, patients with endstage renal disease (CL_{cr} < 10 mL/min/1.73m²) have not been studied.

Hepatic Dysfunction

The pharmacokinetics of tamsulosin hydrochloride have been compared in 8 subjects with The pharmacokinetics of tamsulosin hydrochloride have been compared in 8 subjects with moderate hepatic dysfunction (Child-Pugh's classification: Grades A and B) and 8 normal subjects. While a change in the overall plasma concentration of tamsulosin hydrochloride was observed as the result of altered binding to AAG, the unbound (active) concentration of tamsulosin hydrochloride does not change significantly with only a modest (32%) change in intrinsic clearance of unbound tamsulosin hydrochloride. Therefore, patients with moderate hepatic dysfunction do not require an adjustment in FLOMAX capsules dosage.

Drug-Drug Interactions Nifedipine, Atenolol, Enalapril

In three studies in hypertensive subjects (age range 47-79 years) whose blood pressure was controlled with stable doses of Procardia XL®, atenolol, or enalapril for at least three months, FLOMAX capsules 0.4 mg for seven days followed by FLOMAX capsules 0.8 mg for another seven days (n=8 per study) resulted in no clinically significant effects on blood pres-sure and pulse rate compared to placebo (n=4 per study). Therefore, dosage adjustments are not necessary when FLOMAX capsules are administered concomitantly with Procardia XL®, atenolol, or enalapril.

Warfarin A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited *in vitro* and *in vivo* studies are inconclusive. Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.

Diaoxin and Theophylline

In two studies in healthy volunteers (n=10 per study; age range 19-39 years) receiving In two studies in nearny voluntees (n=10 per study; age range 19-39 years) receiving FLOMAX capsules 0.4 mg/day for two days, followed by FLOMAX capsules 0.8 mg/day for five to eight days, single intravenous does of digoxin 0.5 mg or theophylline 5 mg/kg result-ed in no change in the pharmacokinetics of digoxin or theophylline. Therefore, dosage adjustments are not necessary when a FLOMAX capsule is administered concomitantly with digoxin or theophylline.

The pharmacokinetic and pharmacodynamic interaction between Flomax® (tamsulosin hydrochloride) capsules 0.8 mg/day (steady-state) and furosemide 20 mg intravenously (sin gle dose) was evaluated in ten healthy volunteers (age range 21-40 years). FLOMAX cap-sules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in tamsulosin hydrochloride C. and AUC, these changes are expected to be clinically insignificant and do not require adjust ment of the FLOMAX capsules dosage.

5.0 14.9 ± 3.9 557 ± 257

Cimetidine The effects of cimetidine at the highest recommended dose (400 mg every six hours for six days) on the pharmacokinetics of a single FLOMAX capsule 0.4 mg dose was investigated in ten healthy volunteers (age range 21-38 years). Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%). Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg

CLINICAL STUDIES Four placebo-controlled clinical studies and one active-controlled clinical study enrolled a total of 2296 patients (1003 received FLOMAX capsules 0.4 mg once daily, 491 received FLOMAX capsules 0.8 mg once daily, and 802 were control patients) in the U.S. and Europe

In the two U.S. placebo-controlled, double-blind, 13-week, multicenter studies [Study 1 (US92-03A) and Study 2 (US93-01)], 1486 men with the signs and symptoms of BPH were enrolled. In both studies, patients were randomized to either placebo, FLOMAX capsules 0.4 mg once daily, or FLOMAX capsules 0.8 mg once daily. Patients in FLOMAX capsules 0.8 mg once daily treatment groups received a dose of 0.4 mg once daily for one week before increasing to the 0.8 mg once daily dose. The primary efficacy assessments included: 1) total American Urological Association (AUA) Symptom Score questionnaire, which evaluated irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete empty-ing, intermittency, and weak stream) symptoms, where a decrease in score is consistent with improvement in symptoms; and 2) neak urine flow rate, where a nicreased neak urgen flow wement in symptoms; and 2) peak urine flow rate, where an increased peak urine flow rate value over baseline is consistent with decreased urinary obstruction.

Mean changes from baseline to week 13 in total AUA Symptom Score were significantly greater for groups treated with FLOMAX capsules 0.4 mg and 0.8 mg once daily compared to placebo in both U.S. studies (Table 2, Figures 2A and 2B). The changes from baseline to week 13 in peak urine flow rate were also significantly greater for the FLOMAX capsules 0.4 mg and 0.8 mg once daily groups compared to placebo in Study 1, and for the FLOMAX capsules 0.4 sules 0.8 mg once daily group in Study 2 (Table 2, Figures 3A and 3B). Overall there were no significant differences in improvement observed in total AUA Symptom Scores or peak urine flow rates between the 0.4 mg and the 0.8 mg does erroups with the excention that the 0.8 flow rates between the 0.4 mg and the 0.8 mg dose groups with the exception that the 0.8 mg dose in Study 1 had a significantly greater improvement in total AUA Symptom Score compared to the 0.4 mg dose.

Table 2 Mean (±S.D.) Changes from Baseline to Week 13 in Total AUA Sympton Score ** and Peak Urine Flow Rate (mL/sec)

	Total AUA Symptom Score		Peak Urine Flow Rate	
	Mean Baseline	Mean	Mean Baseline	Mean
	Value	Change	Value	Change
Study 1 †				
FLOMAX capsules	19.9±4.9	-9.6*±6.7	9.57±2.51	1.78*±3.35
0.8 mg once daily	n=247	n=237	n=247	n=247
FLOMAX capsules	19.8±5.0	-8.3*±6.5	9.46±2.49	1.75*±3.57
0.4 mg once daily	n=254	n=246	n=254	n=254
Placebo	19.6±4.9	-5.5±6.6	9.75±2.54	0.52±3.39
	n=254	n=246	n=254	n=253
Study 2 ‡				
FLOMAX capsules	18.2±5.6	-5.8*±6.4	9.96±3.16	1.79*±3.36
0.8 mg once daily	n=244	n=238	n=244	n=237
FLOMAX capsules	17.9±5.8	-5.1*±6.4	9.94±3.14	1.52±3.64
0.4 mg once daily	n=248	n=244	n=248	n=244
Placebo	19.2±6.0	-3.6±5.7	9.95±3.12	0.93±3.28
	n=239	n=235	n=239	n=235

 n=239
 n=235
 n=239
 n=235

 *
 Statistically significant difference from placebo (p-value ≤ 0.050; Bonferroni-Holm multiple test procedure);

 **
 Total AUA Symptom Scores ranged from 0 to 35.

 †
 Peak urine flow rate measured 4 to 8 hours post dose at Week 13.


 ‡
 Peak urine flow rate measured 24 to 27 hours post dose at Week 13.

 Week 13:
 For patients not completing the 13 week study the last observation was carried forward.

Mean total AUA Symptom Scores for both Flomax[®] (tamsulosin hydrochloride) capsules 0.4 mg and 0.8 mg once daily groups showed a rapid decrease starting at one week after dosing and remained decreased through 13 weeks in both studies (Figures 2A and 2B).

In Study 1, 400 patients (53% of the originally randomized group) elected to continue in their originally assigned treatment groups in a double-blind, placebo controlled, 40 week extension trial (138 patients on 0.4 mg, 135 patients on 0.8 mg and 127 patients on placebo). Three hundred and twenty-three patients (43% of the originally randomized group) completed one year. Of these, 81% (97 patients) on 0.4 mg, 74% (75 patients) on 0.8 mg and 56% (57 patients) on placebo had a response ≥25% above baseline in total AUA patients

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0-35) Study




indicates significant difference from placebo (p-value ≤0.050).
 B = Baseline determined approximately one week prior to the initial dose of double-blind medication at Week 0. Subsequent values are observed cases.
 LOCF = Last observation carried forward for patients not completing the 13-week study.

received 0.4 mg for the first week

Note: Patients in the 0.8 mg treatment group received Note: Total AUA Symptom Scores range from 0 to 35.

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0-35) Study 2



* indicates significant difference from placebo (p-value ≤0.050). Baseline measurement was taken Week 0. Subsequent values are observed cases. LOCF = Last observation carried forward for patients not completing the 13-week study. Note: Patients in the 0.8 mg treatment group received 0.4 mg for the first week. Note: Total AUA Symptom Scores range from 0 to 35.

Flomax[®] (tamsulosin hydrochloride) Capsules,0.4 mg

PATIENT INFORMATION ABOUT FLOMAX CAPSULES

FLOMAX capsules are for use by men only. FLOMAX capsules are not indicated for use in women.

Please read this leaflet before you start taking FLOMAX capsules. Also, read it each time you renew your prescription, just in case new information has been added. Remember, this leaflet does not take the place of careful discussions with your doctor. You and your doctor should discuss FLOMAX capsules when you start taking your medication and at regular checkups.

Why your doctor has prescribed FLOMAX capsules?

Your doctor has prescribed FLOMAX cap-sules because you have a medical condition called benign prostatic hyperplasia or BPH. This occurs only in men.

What is BPH?

Benign prostatic hyperplasia is an enlargement of the prostate gland. After age 50, most men develop enlarged prostates. The prostate is located below the bladder. As the prostate is located below may slowly restrict the flow of urine. This can lead to symptoms such as:

- a weak or interrupted urinary stream a feeling that you cannot empty your bladder completely
- a feeling of delay or hesitation when
- you start to urinate a need to urinate often, especially at
- night a feeling that you must urinate right awav

Since cancer of the prostate may cause similar symptoms, you should be evaluated by your doctor to rule out prostate cancer. Your doctor will likely examine your prostate gland manually to detect abnormalities and may measure prostate specific antigen (PSA) in your blood to help in evaluating for the presence of prostate cancer. FLOMAX capsules do not affect PSA levels.

Treatment Options for BPH

There are three main treatment options for BPH:

- Program of monitoring or "Watchful Waiting". Some men have an enlarged prostate gland, but no symptoms, or symptoms that are not bothersome. If this applies, you and your doctor may decide on a program of monitoring, including regular checkups, instead of medication or surgery.
- There are different kinds of medication used to treat BPH. Your doctor has prescribed Flomax[®] (tamsulosin hydrochloride) capsules for you (see What a FLOMAX capsule does to treat BPH) below
- Surgery. Some patients may need surgery. Your doctor can describe sev-eral different surgical procedures to treat BPH. Which procedure is best depends on your symptoms and medical condition.

What a FLOMAX capsule does to treat BPH

FLOMAX capsules act by relaxing muscles in the prostate and bladder neck at the site of the obstruction, resulting in improved urine flow and reduced BPH symptoms.

What you need to know while taking Flomax[®] (tamsulosin hydrochlorid cansules

· You must see your doctor regularly.

- While taking FLOMAX capsules, you must have regular checkups. Follow your doctor's advice about when to ave these checkups.
- It is important for you to recognize that FLOMAX capsules can cause a sudden drop in blood pressure espe cially following the first dose or when changing doses of FLOMAX capsules. Such a drop in blood pressure, although rare in occurrence. may be associated with fainting, dizziness, or lightheadedness. Therefore, get up slowly from a chair or bed at any time until you learn how you react to FLOMAX capsules You should not drive or do any hazardous tasks until you are used to the side effects of FLOMAX capsules. If you begin to feel dizzy, sit down until you feel better. Although these symptoms are unlikely, you should avoid driving or hazardous tasks for 12 hours after the initial dose or after your doctor recommends an increase in dose. If vou interrupt your treatment for several days or more, resume treatment at one capsule a day, after consulting with your physician. Other side effects may include sleeplessness, runny nose, or ejaculatory problems. In some cases, side effects may decrease or disappear when you continue to take FLOMAX capsules.
- Extremely rarely, FLOMAX capsules and similar medications have caused prolonged, painful erection of the penis, which is unrelieved by sexual intercourse or masturbation. This condition, if untreated, can lead to permanent inability to have an erection. If you have a prolonged erection, call your doctor or go to an Emergency Room as soon as possible.
- If you are contemplating cataract surgery, make certain to advise your eye surgeon that you have taker FLOMAX capsules.

You should discuss side effects with your doctor before taking Flomax® (tamsulosin hydrochloride) capsules and anytime you think you are having a side effect.

How to take FLOMAX capsules

Follow your doctor's advice about how to take FLOMAX capsules. You should take it approximately 30 minutes following the same meal every day.

Do not share FLOMAX capsules with anyone else; it was prescribed only for you.

Do not crush, chew, or open capsules of FLOMAX capsules

Keep FLOMAX capsules and all medicines out of reach of children.

FOR MORE INFORMATION ABOUT FLOMAX CAPSULES AND BPH, TALK WITH YOUR DOCTOR. IN ADDITION, TALK TO YOUR PHARMACIST OR OTHER HEALTHCARE PROVIDER



Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and

Astellas Pharma US Inc. Deerfield, IL 60015 USA


Licensed from and Manufactured by:

≯astellas Astellas Pharma Inc. Tokyo 103-8411. IAPAN

Copyright©2006, ALL RIGHTS RESERVED

IT8004B TEAR Revised: July 19, 2006 HERE PRT36/US/1 Printed in U.S.A


Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1



indicates significant difference from placebo (p-value ≤0.050).
 B = Baseline determined approximately one week prior to the initial dose of double-bling medication at Week 0. Subsequent values are observed cases.
 LOCF = Last observation carried forward for patients not completing the 13-week study.
 Note: The uroflowmetry assessments at week 0 were recorded 4-8 hours after patients received the first dose of double-blind medication.
 Magaurements at each with the restricted to the second second

Measurements at each visit were scheduled 4-8 hours after dosing (approximately peak plasma tamsulosin concentration). Note: Patients in the 0.8 mg treatment groups received 0.4 for the first week

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2



* indicates significant difference from placebo (p-value ≤0.050). Baseline measurement was taken Week 0. Subsequent values are observed cases. LOCF = Last observation carried forward for patients not completing the 13-week study. Note: Patients in the 0.8 mg treatment group received 0.4 mg for the first week. Note: Week 1 and Week 2 measurements were scheduled 4-8 hours after dosing (approxi-mate peak plasma tamsulosin concentration). All other visits were scheduled 24-27 hours after dosing (approximate trough tamsulosin concentration).

INDICATIONS AND USAGE

VUICATIONS AND USAGE Iomax® (Lamsulosin hydrochloride) capsules are indicated for the treatment of the signs nd symptoms of benign prostatic hyperplasia (BPH). FLOMAX capsules are not indicated for the treatment of hyperte

WARNINGS

detected more frequently in FLOMAX capsule treated patients than in placebo recipients. As with other alpha-adrenergic blocking agents there is a potential risk of syncope (see ADVERSE REACTIONS)

Patients beginning treatment with FLOMAX capsules should be cautioned to avoid situa where injury could result should syncope occur.

Rarely (probably less than one in fifty thousand patients), tamsulosin, like other alpha antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly reated, patients must be advised about the seriousness of the condition (see PRECAUTIONS. Information for Patients)

PRECAUTIONS

General 1. Carcino Carcinoma of the prostate: Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently co-exist. Patients should be evaluated prior to the start of FLOMAX capsules therapy to rule out the presence of carcinoma of the prostate

- Intraoperative Floppy Iris Syndrome; Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers, includ-2. 1 ules. Most reports were in patients taking the alpha-1 blocker when IFIS occurred, but in some cases, the alpha-1 blocker had been stopped prior to surgery In most of these cases, the alpha-1-blocker had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patient had been off the alpha-1 blocker for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syn-drome and is characterized by the combination of a flaccid iris that billows in response to nse to drome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs and potential prolapse of the iris toward the pha-coemulsification incisions. The patient's ophthalmologist should be prepared for possi-ble modifications to their surgical technique, such as the utilization of iris hooks, iris dila-tor rings, or viscoelastic substances. The benefit of stopping alpha-1 blocker therapy prior to cataract surgery has not been established.
- Sulfa Allergy: In patients with sulfa allergy, allergic reaction to Flomax® (tamsulosin hydrochloride) capsules has been rarely reported. If a patient reports a serious or life threatening sulfa allergy, caution is warranted when administering FLOMAX capsules.

Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. . Drug-Drug Int

The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investi-gated. The results indicate significant changes in tamsulosin hydrochloride clearance (26% decrease) and AUC (44% increase). Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.

Results from limited in vitro and in vivo drug-drug interaction studies between tamsu losin hydrochloride and warfarin are inconclusive. Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.

See also Drug-Drug Interactions studies in CLINICAL PHARMACOLOGY, netics subsection.

Information for Patients (see PATIENT INFORMATION ABOUT FLOMAX CAPSULES) Patients should be told about the possible occurrence of symptoms related to postural hypotension such as dizziness when taking FLOMAX capsules, and they should be cautioned

Patients should be advised not to crush, chew or open the FLOMAX capsules.

about driving, operating machinery or performing hazardous tasks

Patients should be advised about the possibility of priapism as a result of treatment with FLOMAX capsules and other similar medications. Patients should be informed that this reaction is extremely rare, but if not brought to immediate medical attention, can lead to per-manent erectile dysfunction (impotence).

Patients should be advised that if they are c mologist that they have taken FLOMAX cap

Laboratory Tests No laboratory test interactions with Flomax[®] (tamsulosin hydrochloride) capsules are known. Treatment with FLOMAX capsules for up to 12 months had no significant effect on prostatespecific antigen (PSA).

Pregnancy

Pregnancy Teratogenic Effects, Pregnancy Category B. Administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to 300 mg/kg/day (approximately 50 times the human therapeutic AUC exposure) revealed no evi-dence of harm to the fetus. Administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. FLOMAX capsules or not indicated for use in unemper are not indicated for use in w

Geriatric Use

Of the total number of subjects (1.783) in clinical studies of tamsulosin, 36% were 65 years Of the total number of subjects (1,783) in clinical studies of famsulosin, 35% were by years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater ser sitivity of some older individuals cannot be ruled out (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations, Geriatrics (Age)).

Nursing Mothers FLOMAX capsules are not indicated for use in women

Pediatric Use

FLOMAX capsules are not indicated for use in pediatric populations.

Carcinogenesis, Mutagenesis, and Impairment of Fertility Rats administered doses up to 43 mg/kg/day in males and 52 mg/kg/day in females had no increases in tumor incidence with the exception of a modest increase in the frequency of mammary gland fibroadenomas in female rats receiving doses ≥ 5.4 mg/kg (P < 0.015). The highest doses of tamsulosin hydrochloride evaluated in the rat carcinogenicity study pro-duced systemic exposures (AUC) in rats 3 times the exposures in men receiving the maxi-mum theraneutic dose of 0.8 mg/day. mum therapeutic dose of 0.8 mg/day.

Mice were administered doses up to 127 mg/kg/day in males and 158 mg/kg/day in Mice were administered doses up to 127 mg/kg/day in males and 158 mg/kg/day in females. There were no significant tumor findings in male mice. Female mice treated for 2 years with the two highest doses of 45 and 158 mg/kg/day had statistically significant increases in the incidence of mammary gland fibroadenomas (P<0.0001) and adenocarcino-mas (P<-0.0075). The highest dose levels of tamsulosin hydrochloride evaluated in the mice carcinogenicity study produced systemic exposures (AUC) in mice 8 times the exposures in men receiving the maximum therapeutic dose of 0.8 mg/day.

The increased incidences of mammary gland neoplasms in female rats and mice were considered secondary to tamsulosin hydrochloride-induced hyperprolactinemia. It is not known if Flomax[®] (tamsulosin hydrochloride) capsules elevate prolactin in humans. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is not known

Tamsulosin hydrochloride produced no evidence of mutagenic potential *in vitro* in the Ames reverse mutation test, mouse lymphoma thymidine kinase assay, unscheduled DNA repair synthesis assay, and chromosomal aberration assays in Chinese hamster ovary cells or human lymphocytes. There were no mutagenic effects in the *in vivo* sister chromatid evidence and merce microsochem certain the *in vivo* sister chromatid exchange and mouse micronucleus assay.

Studies in rats revealed significantly reduced fertility in males dosed with single or multiple daily doses of 300 mg/kg/day of tamsulosin hydrochloride (AUC exposure in rats about 50 times the human exposure with the maximum therapeutic dose). The mechanism of decreased fertility in male rats is considered to be an effect of the compound on the vaginal decreased fertility in male rats is considered to be an effect of the compound on the vaginal plug formation possibly due to changes of semen content or impairment of ejaculation. The effects on fertility were reversible showing improvement by 3 days after a single dose and 4 weeks after multiple dosing. Effects on fertility in males were completely reversed within nine weeks of discontinuation of multiple dosing. Multiple doses of 10 and 100 mg/kg/day tamsulosin hydrochloride (1/5 and 16 times the anticipated human AUC exposure) did not significantly alter fertility in male rats. Effects of tamsulosin hydrochloride on sperm counts or sperm function have not been evaluated or sperm function have not been evalu

Studies in female rats revealed significant reductions in fertility after single or multiple dosing with 300 mg/kg/day of the R-isomer or racemic mixture of tamsulosin hydrochloride sectively. In female rats, the reductions in fertility after single doses were considered to be octated with impairments in fertilization. Multiple dosing with 10 or 100 mg/kg/day of racemic mixture did not significantly alter fertility in female rats. respectively. In fer

ADVERSE REACTIONS

The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S. and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg FLOMAX capsules were used. These studies evaluated safety in 1783 patients treated with FLOMAX capsules and 798 patients administered placebo. Table 3 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either FLOMAX capsules 0.4 mg, or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487

Treatment Emergent¹ Adverse Events Occurring in ≥2% of Flomax[®] (tamsu losin hydrochloride) capsules or Placebo Patients in Two U.S. Short-Term Placebo-Controlled Clinical Studies Table 3

BODY SYSTEM/	FLOMAX CAPSULES GROUPS		PLACEBO
ADVERSE EVENT	0.4 mg	0.8 mg	
	n=502	n=492	n=493
BODY AS WHOLE			
Headache	97 (19.3%)	104 (21.1%)	99 (20.1%)
Infection ²	45 (9.0%)	53 (10.8%)	37 (7.5%)
Asthenia	39 (7.8%)	42 (8.5%)	27 (5.5%)
Back Pain	35 (7.0%)	41 (8.3%)	27 (5.5%)
Chest Pain	20 (4.0%)	20 (4.1%)	18 (3.7%)
NERVOUS SYSTEM			
Dizziness	75 (14.9%)	84 (17.1%)	50 (10.1%)
Somnolence	15 (3.0%)	21 (4.3%)	8 (1.6%)
Insomnia	12 (2.4%)	7 (1.4%)	3 (0.6%)
Libido Decreased	5 (1.0%)	10 (2.0%)	6 (1.2%)
RESPIRATORY SYSTEM			
Rhinitis ³	66 (13.1%)	88 (17.9%)	41 (8.3%)
Pharyngitis	29 (5.8%)	25 (5.1%)	23 (4.7%)
Cough Increased	17 (3.4%)	22 (4.5%)	12 (2.4%)
Sinusitis	11 (2.2%)	18 (3.7%)	8 (1.6%)
DIGESTIVE SYSTEM			
Diarrhea	31 (6.2%)	21 (4.3%)	22 (4.5%)
Nausea	13 (2.6%)	19 (3.9%)	16 (3.2%)
Tooth Disorder	6 (1.2%)	10 (2.0%)	7 (1.4%)
UROGENITAL SYSTEM			
Abnormal Ejaculation	42 (8.4%)	89 (18.1%)	1 (0.2%)
SPECIAL SENSES			
Blurred Vision	1 (0.2%)	10 (2.0%)	2 (0.4%)

1 A treatment-emergent adverse event was defined as any event satisfying one of the foling criteria

IT8004B PRT36/US/1 Revised: July 19, 2006 Printed in USA

- · The adverse event occurred for the first time after initial dosing with double-blind study medication. The adverse event was present prior to or at the time of initial dosing with double-
- blind study medication and subsequently increased in severity during double treatment; or The adverse event was present prior to or at the time of initial dosing with double-
- lind study medication, disappeared completely, and then reappeared during dou le-blind treatment e-blind treatment. ng preferred terms also include cold, common cold, head cold, flu, and flu-like 2 00
- 3 Coding preferred terms also include nasal congestion, stuffy nose, runny nose, sinus on and hav fever

Signs and Symptoms of Orthostasis: In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group and 0.6% of patients (3 of 493) in the placebo group. Dizziness was reported by 15% of patients (75 of 502) in the 0.4 mg group, 1% of patients (84 of 492) in the 0.8 mg group, and 10% of patients (50 of 493) in the placebo group. Vertigo was reported by 0.6% of patients (3 of 502) in the 0.4 mg group, 1% of patients (64 of 492) in the 0.8 mg group, 10% of patients (3 of 502) in the 0.4 mg group, 1% of patients (5 of 492) in the 0.8 mg group, 1% of patients (5 of 492) in the 0.8 mg group, 10% of patients (3 of 502) in the 0.4 mg group, 1% of patients (5 of 492) in the 0.8 mg group, 10% of patients (5 of 493) in the placebo group. mg group and by 0.6% of patients (3 of 493) in the placebo group.

Multiple testing for orthostatic hypotension was conducted in a number of studies. Such a Multiple testing for orthostatic hypotension was conducted in a number of studies. Such a test was considered positive if it met one or more of the following criteria: (1) a decrease in systolic blood pressure of ≥ 20 mmHg upon standing from the supine position during the orthostatic tests; (2) a decrease in diastolic blood pressure ≥ 10 mmHg upon standing, with the standing diastolic blood pressure <55 mmHg during the orthostatic test; (3) an increase in pulse rate ≥ 200 bym upon standing with a standing pulse rate ≥ 100 bym during the orthostatic test; and (4) the presence of clinical symptoms (faintness, lightheadedness/lightheaded, dizziness, spinning sensation, vertigo, or postural hypotension) upon standing during the rate with state test. ing the orthostatic test.

Following the first dose of double-blind medication in Study 1, a positive orthostatic test Following the first dose of double-blind medication in Study 1, a positive orthostatic test result at 4 hours post-dose was observed in 7% of patients (37 of 498) who received Flomax[®] (tamsulosin hydrochloride) capsules 0.4 mg once daily and in 3% of the patients (8 of 253) who received placebo. At 8 hours post-dose, a positive orthostatic test result was observed for 6% of the patients (31 of 498) who received FLOMAX capsules 0.4 mg once daily and 4% (9 of 250) who received placebo (Note: patients in the 0.8 mg group received 0.4 mg once daily for the first week of Study 1).

In Studies 1 and 2, at least one positive orthostatic test result was observed during the course of these studies for 81 of the 502 patients (16%) in the FLOMAX capsules 0.4 mg once daily group, 92 of the 491 patients (19%) in the FLOMAX capsules 0.8 mg once daily group and 54 of the 493 patients (11%) in the placebo group.

Because orthostasis was detected more frequently in FLOMAX capsule-treated patients than in placebo recipients, there is a potential risk of syncope (see WARNINGS).

Abnormal Ejaculation: Abnormal ejaculation includes ejaculation failure, ejaculation disor-der, retrograde ejaculation and ejaculation decrease. As shown in Table 3, abnormal ejacula-tion was associated with FLOMAX capsules administration and was dose-related in the U.S. studies. Withdrawal from these clinical studies of FLOMAX capsules because of abnormal ejaculation was also dose-dependent with 8 of 492 patients (1.6%) in the 0.8 mg group, and no patients in the 0.4 mg or placebo groups discontinuing treatment due to abnor mal eiaculation

Post-Marketing Experience

Post-Marketing Experience The following adverse reactions have been identified during post-approval use of FLOMAX capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal rela-tionship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to FLOMAX capsules. Allergic-type reac-tions such as skin rash, pruritus, angioedema of tongue, lips and face and urticaria have been reported with positive rechallenge in some cases. Priapism has been reported rarely. Infrequent reports of nabilitations, hworension, skin desquaration, constination and vomit Infrequent reports of palpitations, hypotension, skin desquamation, constipation and vo ing have been received during the post-marketing period.

During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha-1 blocker therapy (see PRE-CAUTIONS, General).

OVERDOSAGE

Should overdosage of Flomax[®] (tamsulosin hydrochloride) capsules lead to hypotension (see WARNINGS and ADVERSE REACTIONS), support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accom-plished by keeping the patient in the supine position. If this measure is inadequate, then ation of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; there eeded. Laboratory is unlikely to be of benefit.

One patient reported an overdose of thirty 0.4 mg FLOMAX capsules. Follo tion of the capsules, the patient reported a severe headache.

DOSAGE AND ADMINISTRATION FLOMAX capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day.

For those patients who fail to respond to the 0.4 mg dose after two to four weeks of dosing, the dose of FLOMAX capsules can be increased to 0.8 mg once daily. If FLOMAX capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once daily dose.

HOW SUPPLIED

FLOMAX capsules 0.4 mg are supplied in high density polyethylene bottles containing 100 hard gelatin capsules with olive green opaque cap and orange opaque body. The cap are imprinted on one side with "Flomax 0.4 mg" and on the other side with "BI 58."

FLOMAX capsules 0.4 mg, 100 capsules (NDC 0597-0058-01)

Store at 25° C (77° F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled

Keep FLOMAX capsules and all medicines out of reach of children Patients should be reminded to read and follow the accompanying "PATIENT INFORMA-TION ABOUT FLOMAX CAPSULES", which should be dispensed with the product.

Marketed by:

Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and

Astellas Pharma US, Inc. Deerfield, IL 60015 USA Licensed from and Manufactured by

astellas

Astellas Pharma Inc. Tokyo 103-8411, JAPAN Copyright©2006, ALL RIGHTS RESERVED

CONTRAINDICATIONS FLOMAX capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of FLOMAX capsules. The signs and symptoms of orthostasis (postural hypotension, dizziness and vertigo) were